Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Atezolizumab in Combination With Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery for Patients With Newly-Diagnosed Advanced-Stage Epithelial Ovarian Cancer

NCT03394885 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT03394885
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03394885 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Atezolizumab in Combination With Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery for Patients With Newly-Diagnosed Advanced-Stage Epithelial Ovarian Cancer
Lead sponsor
Duke University
Phase
Phase 1/2
Overall status
Completed
Start date
June 19, 2018
Completion date
July 20, 2020
Enrollment
18 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, ovarian neoplasms